Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma-Reference-Cited by-同舟云学术

Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma

Published:2010-03-16 Issue:11 Volume:116 Page:2655-2664
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ruan Jia,Martin Peter,Coleman Morton,Furman Richard R.,Cheung Ken,Faye Adam,Elstrom Rebecca,Lachs Mark,Hajjar Katherine A.,Leonard John P.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference26 articles.

1. A clinical analysis of 2 indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study;Fisher;Blood.,1995

2. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival;Howard;J Clin Oncol.,2002

3. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG);Lenz;J Clin Oncol.,2005

4. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine;Romaguera;J Clin Oncol.,2005

5. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL networks;Dreyling;Blood.,2005

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules;Cancer Letters;2024-06

2. Metronomic Chemotherapy in Elderly Patients;Current Oncology Reports;2024-03-07

3. Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications;Frontiers in Oncology;2023-05-22

4. Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms;Frontiers in Immunology;2022-10-12

5. Procarbazine, prednisolone and cyclophosphamide oral combination chemotherapy protocol for canine lymphoma;Veterinary and Comparative Oncology;2022-04-02